Launch One Acquisition's (LPAA) merger target Minovia Therapeutics said Monday it has been granted US Food and Drug Administration fast-track designation for its lead investigational compound MNV-201, which is intended as a treatment for Pearson Syndrome.
The company said the FDA also granted the drug candidate rare pediatric disease designation. The drug candidate is in phase 2 clinical trials for the treatment of the disease, the company said.
Launch One, a blank-check company, is expected to close its business combination with Minovia in late 2025, the company said.
Pearson Syndrome is a rare genetic disorder that leads to bone marrow failure, metabolic crises, and organ dysfunction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.